Company Filing History:
Years Active: 1997-2004
Title: Suzanne Lewis: Innovator in Gene Therapy
Introduction
Suzanne Lewis is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of gene therapy, particularly in relation to cardiovascular diseases. With a total of 2 patents, her work focuses on innovative methods to evaluate and reduce the risk of atherosclerosis.
Latest Patents
Among her latest patents is a groundbreaking gene therapy method aimed at reducing the risk of atherosclerosis. This method includes a reagent and kit for evaluating susceptibility to premature coronary artery disease. One notable aspect of her research involves a single point mutation in the human lipoprotein lipase gene, which results in a nucleotide change at codon 291. This mutation is associated with an increased susceptibility to coronary artery disease, particularly premature atherosclerosis. The findings indicate that individuals with this mutation exhibit diminished catalytic activity of lipoprotein lipase, lower HDL-cholesterol levels, and higher triglyceride levels.
Career Highlights
Suzanne has worked at esteemed institutions, including the University of British Columbia. Her research has been pivotal in advancing our understanding of genetic factors contributing to cardiovascular health.
Collaborations
Throughout her career, Suzanne has collaborated with notable professionals in her field, including Michael R. Hayden and Yuanhong Ma. These collaborations have further enriched her research and contributed to her innovative approaches in gene therapy.
Conclusion
Suzanne Lewis stands out as a key figure in the realm of gene therapy, with her innovative patents addressing critical health issues. Her work continues to pave the way for advancements in the understanding and treatment of cardiovascular diseases.